These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 24406295

  • 1. Do androgen deprivation drugs affect the immune cross-talk between mononuclear and prostate cancer cells?
    Salman H, Bergman M, Blumberger N, Djaldetti M, Bessler H.
    Biomed Pharmacother; 2014 Feb; 68(1):21-4. PubMed ID: 24406295
    [Abstract] [Full Text] [Related]

  • 2. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L, Giocanti N, Hennequin C, Favaudon V.
    Prostate; 2010 Mar 01; 70(4):401-11. PubMed ID: 19902473
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.
    Yannucci J, Manola J, Garnick MB, Bhat G, Bubley GJ.
    J Urol; 2006 Aug 01; 176(2):520-5. PubMed ID: 16813881
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Bicalutamide failure in prostate cancer treatment: involvement of Multi Drug Resistance proteins.
    Colabufo NA, Pagliarulo V, Berardi F, Contino M, Inglese C, Niso M, Ancona P, Albo G, Pagliarulo A, Perrone R.
    Eur J Pharmacol; 2008 Dec 28; 601(1-3):38-42. PubMed ID: 18992739
    [Abstract] [Full Text] [Related]

  • 7. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H.
    Br J Cancer; 1999 Sep 28; 81(2):242-51. PubMed ID: 10496349
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Increased resistance to trail-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide.
    Mitterberger M, Neuwirt H, Cavarretta IT, Hobisch A, Culig Z.
    Prostate; 2007 Aug 01; 67(11):1194-201. PubMed ID: 17520660
    [Abstract] [Full Text] [Related]

  • 10. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.
    Gravina GL, Marampon F, Di Staso M, Bonfili P, Vitturini A, Jannini EA, Pestell RG, Tombolini V, Festuccia C.
    Prostate; 2010 Aug 01; 70(11):1166-78. PubMed ID: 20333699
    [Abstract] [Full Text] [Related]

  • 11. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H, Eide T, Krobert KA, Levy FO, Dizeyi N, Bjartell AS, Abrahamsson PA, Taskén KA.
    Prostate; 2008 Jul 01; 68(10):1133-42. PubMed ID: 18454446
    [Abstract] [Full Text] [Related]

  • 12. Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study.
    Tombal B, Cornel EB, Persad R, Stari A, Gómez Veiga F, Schulman C.
    J Urol; 2017 Nov 01; 198(5):1054-1060. PubMed ID: 28552710
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H, Igawa T, Tsurusaki T, Yura M, Kusaba Y, Hayashi M, Iwasaki S, Hakariya H, Hara T, Kanetake H.
    Urology; 2009 Mar 01; 73(3):635-40. PubMed ID: 19038426
    [Abstract] [Full Text] [Related]

  • 15. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
    Kawata H, Arai S, Nakagawa T, Ishikura N, Nishimoto A, Yoshino H, Shiraishi T, Tachibana K, Nakamura R, Sato H.
    Prostate; 2011 Sep 01; 71(12):1344-56. PubMed ID: 21308717
    [Abstract] [Full Text] [Related]

  • 16. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer.
    Colquhoun AJ, Venier NA, Vandersluis AD, Besla R, Sugar LM, Kiss A, Fleshner NE, Pollak M, Klotz LH, Venkateswaran V.
    Prostate Cancer Prostatic Dis; 2012 Dec 01; 15(4):346-52. PubMed ID: 22614062
    [Abstract] [Full Text] [Related]

  • 17. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer.
    Akaza H.
    BJU Int; 2007 Jan 01; 99 Suppl 1():10-2; discussion 17-8. PubMed ID: 17229161
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N, Arima K, Sugimura Y.
    Jpn J Clin Oncol; 2008 Sep 01; 38(9):617-22. PubMed ID: 18697759
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.